Related Experiment Video
Updated: Aug 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Serevent in the treatment of moderate bronchial asthma]
Abstract:
A group of 20 patients with moderate bronchial asthma aged 18 through 65, previously treated with Becotide inhaler for 4 weeks was given Serevent in regular dosage for 4 weeks. Serevent efficiency was assessed clinically and functionally (MEVS, IPB). A progressive improvement of all clinical and functional parameters was obtained following the treatment. The evolution was unsatisfactory with 3 cases which entered the group with advanced asthma condition. No adverse reaction of tachyphylaxis manifestations were recorded. Drug adequacy was perfect. The final results place Serevent among elective bronchodilators in long-time ambulatory treatment.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
COPD: Management Using Bronchodilators and Corticosteroids
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications

